JAZZ

Jazz Pharmaceuticals Plc - Q1 2009 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2009. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for neurology and psychiatry. Key marketed products include Xyrem (sodium oxybate) for narcolepsy and Luvox CR (fluvoxamine maleate) for obsessive compulsive disorder and social anxiety disorder. The company is currently in Phase III clinical trials for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 51% to $22.1 million, driven by a 56% increase in Xyrem sales ($17.7 million) and the launch of Luvox CR ($3.6 million), offset by the divestiture of Antizol rights in August 2008.
• Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell 46% to $11.4 million, and Selling, General, and Administrative (SG&A) expenses dropped 57% to $14.2 million, largely due to workforce reductions and cost-cutting measures implemented in 2008.
• Debt Default: The company failed to make quarterly interest payments of $4.5 million (due Dec 31, 2008) and $5.1 million (due March 31, 2009) on its Senior Secured Notes. This triggered an event of default, increasing the interest rate to 17% and classifying the debt as a current liability.
• Liquidity: Cash and cash equivalents decreased by $7.9 million during the quarter. The company repaid its line of credit ($3.9 million) and did not have sufficient cash to meet restricted cash covenants tied to the Senior Notes.

Outlook, Risks, and Management Commentary

• Going Concern: Management states that recurring losses and net capital deficiency raise substantial doubt about the company's ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
• Financing Needs: The company is actively seeking financing and strategic alternatives. Current cash resources are sufficient to fund operations but not sufficient to fund operations plus debt service. Failure to raise capital could force the company to curtail development programs (including JZP-6), scale back commercial operations, or seek bankruptcy protection.
• Debt Restructuring: The company is in discussions with holders of the Senior Notes (primarily LB I Group Inc., an affiliate of Lehman Brothers) regarding the defaults. Holders have the right to accelerate payment of the full principal amount, which the company cannot repay.
• Product Outlook: Sales of Luvox CR have been lower than anticipated. The company expects preliminary data from the second Phase III trial for JZP-6 in mid-2009. If successful, an NDA is planned for the fourth quarter of 2009.
• Stock Listing Risk: The company's common stock is at risk of delisting from The NASDAQ Global Market due to failure to meet minimum bid price and market value requirements.

Investor Verification Checklist

• Debt Acceleration Status: Verify if the Senior Note holders have issued a notice of acceleration requiring immediate repayment of the $119.5 million principal plus accrued interest.
• Capital Raise Progress: Confirm the status of ongoing discussions for debt restructuring, equity financing, or strategic partnerships to resolve the liquidity crisis.
• JZP-6 Clinical Data: Monitor the release of preliminary results from the second Phase III pivotal trial for JZP-6 (expected mid-2009), which is critical for future valuation.
• Luvox CR Sales Trajectory: Assess whether Luvox CR sales are stabilizing or continuing to underperform relative to the amended payment obligations to Solvay.
• NASDAQ Compliance: Track the company's ability to regain compliance with NASDAQ listing standards to avoid delisting.